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Summary
Non-digestible milk oligosaccharides were proposed
as receptor decoys for pathogens and as nutrients for
beneficial gut commensals like bifidobacteria. Bovine
milk contains oligosaccharides, some of which are
structurally identical or similar to those found in
human milk. In a controlled, randomized double-
blinded clinical trial we tested the effect of feeding a
formula supplemented with a mixture of bovine milk-
derived oligosaccharides (BMOS) generated from
whey permeate, containing galacto-oligosaccharides
and 3’- and 6’-sialyllactose, and the probiotic
Bifidobacterium animalis subsp. lactis (B. lactis)
strain CNCM I-3446. Breastfed infants served as ref-
erence group. Compared with a non-supplemented
control formula, the test formula showed a similar
tolerability and supported a similar growth in healthy
newborns followed for 12 weeks. The control, but not
the test group, differed from the breast-fed reference
group by a higher faecal pH and a significantly higher
diversity of the faecal microbiota. In the test group the
probiotic B. lactis increased by 100-fold in the stool
and was detected in all supplemented infants. BMOS
stimulated a marked shift to a bifidobacterium-
dominated faecal microbiota via increases in endog-
enous bifidobacteria (B. longum, B. breve, B. bifidum,
B. pseudocatenulatum).
Introduction
After deciphering the sequence of the human genome,
the scientific community ‘discovered’ our second genome:
that of microbes colonizing our body (Ding and Schloss,
2014; Human Microbiome Project Consortium, 2012a,b).
Advances in sequencing technologies have allowed a
deep look into this world of microbial symbionts. Most
research went into the gut microbiota revealing its com-
positional complexity (Arumugam et al., 2011), its matu-
ration in infants (Yatsunenko et al., 2012) and its
association with human health and disease states
(Gordon et al., 2012; Saavedra and Dattilo, 2012;
Buccigrossi et al., 2013; Subramanian et al., 2014). What
is far less clear are ways how to change a microbiota
composition from a disease- to a health-associated state
(Brüssow, 2015a,b). Recent data document substantial
success with the transplantation of processed whole
faeces from healthy donors into the gut of patients who
suffer from Clostridium difficile infection (van Nood et al.,
2013; McCune et al., 2014). Because the standardization
of such preparations as ‘bacteriotherapy’ is problematic
from a regulatory viewpoint, more research has been
conducted to develop defined oral supplements such as
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probiotics and prebiotics, which beneficially influence the
gut microbiota composition (Preidis and Versalovic, 2009;
Kumar et al., 2014).
Probiotics are defined as ‘live microorganisms that,
when administered in adequate amounts, confer a health
benefit on the host’. Although this definition does not
specify the microorganisms, most data come from
bifidobacteria and lactobacilli used against gastrointesti-
nal inflammations, infections and allergic conditions.
Prebiotics on the other hand are defined as ‘nonviable
food components that confer a health benefit on the host
associated with the modulation of the microbiota’.
Although the chemical nature of the food component is
again not specified in this definition, most research has
been done with fructo-oligosaccharides (FOS) and
galacto-oligosaccharides (GOS) in the context of gastro-
intestinal and allergic diseases (Mugambi et al., 2012a;
Osborn and Sinn, 2013; van Hoffen et al., 2009). Human
milk oligosaccharides (HMOs) are natural prebiotics
because they represent the bifidogenic factors that favour
the growth of bifidobacteria, which typically dominate the
gut microbiota of breastfed infants (Garrido et al., 2013;
Smilowitz et al., 2014). Current research suggests that
HMOs may represent a ‘glycan code’, which the mother
uses to influence the colonization of the gut in breastfed
infants with beneficial microbes (Zivkovic et al., 2011).
Because HMOs synthesis at large scale is still challeng-
ing, milk oligosaccharides from cow’s milk – although
present at lower concentration and with distinct chemical
specificity – represent an alternative source for a milk-
derived prebiotic in infant formula (Chichlowski et al.,
2011; Zivkovic and Barile, 2011; Barile and Rastall, 2013).
Probiotic and prebiotic approaches have their prob-
lems. Introducing probiotics into the gut already populated
by a large number of indigenous bacteria meets coloniza-
tion resistance from the resident gut microbiota.
Prebiotics, on the other hand, can only affect the growth
and metabolic activities of bacteria that are already
present in the gut, not those that are missing. A possible
solution for these problems is a combination of probiotics
and prebiotics, called a ‘synbiotic’, where the chosen
prebiotic selectively increases the chance of the ingested
probiotic to gain a foothold in the gut (Mugambi et al.,
2012b).
In the study presented here we investigated the impact
of a synbiotic formula on gut microbiota composition in
healthy infants in a double-blinded placebo-controlled
clinical trial. The test formula consisted of BMOS com-
bined with Bifidobacterium animalis subsp. lactis
(B. lactis) strain CNCM I-3446 (Steenhout et al., 2009;
Philippe et al., 2011). The same formula without addition
of the prebiotic–probiotic blend was used in the control
group. Breastfed infants served as reference group. The
test formula with the pre- and probiotic was well tolerated,
and a strong bifidogenic effect was observed, mainly
driven by the prebiotic effect on the indigenous
bifidobacteria.
Results
Nutritional intervention trial
At a mean age of 5 days, 115 healthy full-term infants
were enrolled into a nutritional intervention trial. Infants
from mothers who decided not to breastfeed were
randomized to either a starter infant formula (control
formula C, n = 37, 1.8 g protein/100 kcal; whey/casein
ratio 70:30) or the same formula supplemented with a
prebiotic (BMOS) at a total oligosaccharide concentration
of 5.7 ± 1.0 g/100 g of powder formula (8 g l−1 in the
reconstituted formula) and a probiotic (B. lactis strain
CNCM I-3446 with 1 × 107 cfu g−1 of powder formula) (test
formula T, n = 39) for a 12-week feeding period. Infants
from mothers who decided to exclusively breastfeed were
enrolled in the breastfed group (group B, n = 39), which
served as physiological reference group. Figure 1 pre-
sents the flowchart for infants who were enrolled, lost to
follow-up and analysed for the different outcomes. At
baseline and over the 12-week observation period of the
intention to treat (ITT) population (n = 115 infants), no
significant difference was seen between the three groups
for anthropometric measurements (Tables S1 and S2).
Stool characteristics and infant behaviour
In the per protocol analysis, the number of stools
decreased from 4.9 to 2.4 stools per day over the obser-
vation period, with no difference between the groups
(P > 0.4). During the feeding trial, infants from the T, but
not the C group, showed a proportion of yellowish versus
greenish stools equivalent to B infants (Fig. S1). Infants in
the T group showed during intervention more liquid stools
than infants in the C group; liquid stools were the domi-
nant observation in B infants (Fig. S2). At 6 weeks, infants
in the T and B groups showed a similar stool pH, whereas
C infants showed a significantly higher stool pH
(Tables S3 and S4). Infants from the T and C groups did
not differ in ‘spitting up’, vomiting, crying, colic, flatulence
and irritability (data not shown).
Stool microbiology analysis: quantitative real-time
polymerase chain reaction (PCR)
Stool samples were collected from infants before first
product application and at 6 and 12 weeks of age when on
the allotted feeding regime. In the per protocol analysis,
stools from 18 to 23 infants were available per group and
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time point. When using a universal 16S rRNA gene primer
pair, the nutritional intervention slightly increased the total
bacterial count (Fig. 2 top, left). In average, we obtained
median numbers of 5 × 1010 to 1011 bacterial cells g−1 stool
for all feeding groups and all time points. Subsequently
we used 16S rRNA gene primers allowing taxonomic dif-
ferentiation. Total counts of bifidobacteria increased in all
three groups between enrolment and 6 weeks of age,
Fig. 1. Flowchart of the enrolled infants.
*Several reasons could be reported for the
same subject. Note: due to technical reasons,
36 subjects from the study site in Poland had
no primary outcome measured and were
excluded from the ITT population
(http://www.ema.europa.eu).
Fig. 2. Bacterial counts measured by qPCR in the faeces of infants receiving the specified formula (red = control; green = supplemented test
formula) or who were breastfed (blue) at enrolment (< 2w) and at six (6w) and twelve (12w) weeks of age. qPCR results are given as boxplots
around median of bacterial cells per gram of stool. *P < 0.05; **P < 0.01; ***P < 0.001.
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after which it remained constant until 12 weeks (Fig. 2 top,
middle). Compared with infants in the C group, infants in
the T group showed a more pronounced increase in the
Bifidobacterium titre by 0.8 log. In the T group, the final
faecal titre of bifidobacteria was with 0.8 × 1010
bacteria g−1 stool significantly higher than in the C and in
the B group. Bacteroides and lactobacilli showed a 10-fold
higher and 10-fold lower stool number, respectively, in
infants from the C group compared with those from the T
group (data not shown and Fig. 2 top, right).
To achieve further resolution in the Bifidobacterium
genus, we used a qPCR set of primers based on the
groEL gene that allowed the detection of 12
Bifidobacterium species (Junick and Blaut, 2012).
Bifidobacterium adolescentis, B. animalis, B. bifidum,
B. breve, B. catenulatum, B. dentium, B. longum and
B. pseudocatenulatum were detected (Fig. 2 bottom, and
data not shown). Bifidobacterium longum and B. bifidum
were the dominant bifidobacteria in the test group,
whereas B. bifidum and B. breve dominated the
microbiota in the breastfed and in the control group.
Detection of the added probiotic
Stools positive for B. animalis (to which the subspecies
lactis belongs) by qPCR increased from 6% to 95% after
feeding the test formula and titres increased from 107.1 to
109.4 cells g−1 stool, yet B. lactis remained a minor fraction
of the total bifidobacteria. In contrast, only 13% of the
control formula recipients and 5% of breastfed infants
showed B. lactis in their stools.
Microbiota composition: diversity index
The qPCR analysis allows estimating absolute bacterial
counts in the stool for a defined bacterium but does not
give an untargeted view on the faecal microbiota. There-
fore, the microbiota analysis was complemented by 16S
rRNA gene pyrosequencing. After analysis and exclusion
of subjects with incomplete data sets, we obtained faecal
microbiota compositions for all three time points from at
least 13 infants per group. Figure 3 compares the
α-diversity for the three groups at baseline and after 6 and
12 weeks of feeding. At baseline the three feeding groups
did not differ significantly in microbial diversity (Shannon
index). At 6 weeks of age, infants in the C group showed
a higher diversity index, due to an increase in both rich-
ness and evenness when compared with infants in the T
group and the B group. At 12 weeks of age, the C group
but not the T group differed from the B group with respect
to diversity and richness (Fig. 3).
Microbiota composition: biplot
The bacterial communities of the three groups were ana-
lysed by ordination based on the weighted UniFrac dis-
tance (Fig. 4). The coordinates of the six most abundant
bacterial genera (weighted average of the relative abun-
Fig. 3. Boxplots of alpha-diversity analyses at
three time points for the three feeding groups
using three different indices (panels A–C).
*P < 0.05; **, P < 0.01; ***P < 0.001.
Fig. 4. 3D Principal Coordinate Biplot of Weighted UniFrac
distances. Lines connect the three time points (see colour code) of
each individual. The six most abundant genera are shown as grey
bubbles (see code numbers).
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dance in all samples) is indicated by grey bubbles. All
infants in the T group showed from baseline to 6 weeks of
age a shift to the position of bifidobacteria and remained
there until at least 12 weeks of age. No clear development
towards a Bifidobacterium-dominated faecal microbiota
was seen in the C group at 6 weeks of age. Even at 12
weeks of age not all these children had moved to the
Bifidobacterium coordinates. In the B group, about one
third of the infants did not shift to a Bifidobacterium-
dominated faecal microbiota.
Microbiota composition: taxonomic affiliation of bacteria
Based on 16S rRNA gene sequencing, the microbiota
composition of the stool samples for all individual infants
in each feeding group is displayed in a bubble plot (Fig. 5,
Fig. S3). Bifidobacteria are increased in all three feeding
groups, most prominently in the T and B groups and
substantially less so in the C group. Bifidobacterium
pseudocatenulatum became dominant in B and T, but not
in C group. Two other bifidobacterial species, which were
prominent in all three feeding groups, are B. longum and
B. breve. However, only one Bifidobacterium species
dominated the stool of infants at a given time point.
Bifidobacterium animalis was nearly absent in the B and C
stools, whereas it was detected in practically all faecal
samples of the T group, although with low abundance
(median = 0.7%) (P < 0.001). Escherichia is prominent at
baseline in all three feeding groups and decreases sub-
stantially at 6 weeks and 12 weeks. The decrease is less
prominent in the C group (P < 0.01 compared with other
groups). In the T group Streptococcus is prominent at
baseline and disappears practically at 6 weeks and 12
weeks, whereas it is maintained in C and B infants.
Ruminococcus gnavus, a typical human gut commensal,
dominates some C infants at 6 and 12 weeks of age.
Clostridium perfringens is found with high titres in three B
infants at 6 weeks of age, but not in the two formula
groups, whereas Peptostreptococcaceae were signifi-
cantly more abundant in group C than in group B and T
infants (P < 0.05).
Discussion
The synbiotic intervention had a marked effect on the
development of the gut microbiota. Compared with the
control formula, the supplemented formula induced a shift
in all treated infants towards a Bifidobacterium-dominated
faecal microbiota, which was already apparent after 6
weeks of feeding the test formula. The treatment effect
became also evident when using other common param-
eters in microbiota analyses. For example, at 6 weeks of
age the treated infants showed a significantly lower
diversity index than infants fed the control formula. For
these microbiota parameters infants from the synbiotic
treatment group resembled the breastfed infants who
likewise – albeit less markedly – showed a shift to a
Bifidobacterium-dominated gut microbiota as is commonly
observed in breastfed infants. This comparison should be
interpreted with caution because the breastfed group was
self-selected, and only the subjects from the two formula
groups were randomized at enrolment, thus allowing
direct comparisons only between them. However, overall
the infants from the three feeding groups matched well in
many parameters except that breastfed infants had a
higher gestational age, less caesarean sections and more
siblings than formula-fed infants (data not shown).
What might be the reason for the higher microbiota
diversity in the control group? In recent publications
(Bäckhed et al., 2015; Dogra et al., 2015a) and a review
(Dogra et al., 2015b) three stages of gut colonization were
distinguished in infants during the first year of life: a rela-
tively diverse Proteobacteria-dominated microbiota in the
neonatal period, followed by an Actinobacteria-dominated
more uniform microbiota induced by breastfeeding, which
is then replaced by a more diverse, more adult-like
Firmicutes and Bacteroidetes-dominated microbiota
induced more by the cessation of breastfeeding than by
the introduction of formula feeding or solid-food supple-
mentation. Breastfeeding and as demonstrated in the
current communication also milk oligosaccharide
feeding shifts the gut microbiota to the less
diverse Actinobacteria/Bifidobacterium-dominated stage,
whereas infants fed with a formula initially prolong the
more diverse Proteobacteria-dominated profile and then
develop earlier into an adult-type, more diverse
microbiota.
As we compared a formula containing a combined pre-
and probiotic supplement with an un-supplemented
control formula, we cannot deduce what compound of
the supplement mediated the strong Bifidobacterium-
stimulating effect in the test group. However, the
microbiota analysis provided a clear answer. When using
a species-specific PCR for B. animalis (to which the sup-
plemented probiotic belongs), we observed a robust
increase in the faecal representation of the probiotic,
which was not observed in the control and the breastfed
group indicating a successful introduction of the probiotic
in the gut of the infants in the test group. Mean titres of
B. lactis were with 109.4 cells g−1 stool relatively high.
However, compared with the overall stimulation of
bifidobacteria observed with the synbiotic supplement, the
added probiotic could only account for a small percentage
of the Bifidobacterium-stimulating effect. The major
contributor to this stimulatory effect was clearly the
prebiotic supplement and its effect on the indigenous
bifidobacteria. Our observation concurs with other data on
probiotic supplementation. Larsen and colleagues (2011)
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tested another B. animalis subsp. lactis strain in infants at
a daily dose of 1010 bacteria, and did not observe an
increase in total faecal bifidobacteria compared with that
in controls and pre-intervention, but the probiotic strain
increased from non-detection to 107.6 cells g−1 stool by
qPCR. No impact on bacterial population diversity was
seen. Infants supplemented with 106 bifidobacteria g−1
formula showed an increase in prevalence, but not in
titre of bifidobacteria compared with that in placebo recipi-
ents (Langhendries et al., 1995). Likewise feeding
B. animalis subsp. lactis at 6 × 1010 cells l−1 formula to
full-term infants did not lead to an increased
Bifidobacterium cell count over the control formula
(Bakker-Zierikzee et al., 2005).
How does the stimulatory effect of BMOS prebiotic
compare with other bifidogenic prebiotics? In the literature
only GOS/FOS prebiotics have so far been investigated in
infants for stimulatory effects on faecal bifidobacteria
(Veereman, 2007; Piirainen et al., 2008). Although a
stimulation of faecal bifidobacteria by these prebiotics has
consistently been observed, the degree of stimulation
differs substantially, with some groups reporting only
small or only transient effects. Preterm infants receiving a
formula containing 10 g l−1 GOS/FOS (90:10%) showed a
50-fold higher Bifidobacterium viable stool titre over
preterm infants receiving the same formula without
prebiotic supplements. The difference was significant
after 4 weeks, but not 2 weeks of feeding (Boehm et al.,
2002). A 50-fold increase in the titre of viable
Bifidobacterium was seen in term infants fed with a
formula supplemented with 4 and 8 g l−1 GOS/FOS com-
pared with that in control formula (Moro et al., 2002).
However, another group observed with the same GOS/
FOS mixture only a moderate increase in bifidobacteria,
namely from 50% to 60% of total faecal bacteria, but no
increase in faecal Bifidobacterium counts compared with
that in standard formula (Knol et al., 2005). A transient
increase of bifidobacteria was seen in children between 4
and 8 weeks of age with formula supplemented with 6 g of
GOS/FOS l−1 compared with that in standard formula
(70% vs 50% bifidobacteria of total faecal bacteria)
(Bakker-Zierikzee et al., 2005).
BMOS thus shows a robust bifidobacteria-stimulating
effect that is as high or even higher than FOS/GOS. The
test formula was faster and more efficient (absence of
non-responder) in bringing the infant microbiota to a
bifidobacteria-dominated community, even when com-
pared with the breastfed group. Recent data suggest that
in addition to the composition of the gut microbiota, its rate
of acquisition is important (Bäckhed et al., 2015; Dogra
et al., 2015a). Therefore, the strong and rapid stimulation
of bifidobacteria by the test formula may have a positive
effect on infants. Some authors have suggested that a
general bifidobacteria-stimulating effect is not enough to
achieve health benefits, but that a species-specific
Bifidobacterium stimulation is needed for alleviating
for example allergy-related symptoms (Ouwehand
et al., 2001). The prebiotic supplement stimulated
B. pseudocatenulatum, which was not observed in the
control group. Interestingly, B. pseudocatenulatum is also
a prominent Bifidobacterium species in breastfed infants
strengthening its link to potential health effects. The fact
that specific indigenous bifidobacterial species can be
stimulated by BMOS in vivo offers interesting possibilities
for targeted gut microbiota ‘engineering’ by nutritional
interventions in the future. However, we need to know
more about the relative health-promoting properties of the
different bifidobacterial species to fully exploit the
bifidogenic properties of oligosaccharides. As some
probiotic effects are strain-specific, the synbiotic
approach might allow the targeted stimulation of a given
strain by a specific prebiotic. Because of the design of our
clinical trial we cannot decide whether the increase in
B. lactis is the result of its oral supplementation or
whether its presence was further boosted by the probiotic
supplement. From a biotechnological perspective, it will
be important to explore whether specific prebiotics can be
designed that favour the outgrowth of a specific
bifidobacterial strain tested in competition with other gut-
derived bifidobacteria by in vitro tests and whether this
specific stimulatory activity is translated into the in vivo
situation.
Our study was powered to demonstrate non-inferiority
for the test formula compared with the control formula for
growth. This goal was achieved. All anthropometric
parameters (weight gain, length and head circumference)
did not differ between groups from inclusion until 3
months of age. The study was not powered to detect
differences in health outcomes. In fact, only three infec-
tions were observed and distributed evenly across the
three groups. Were there observations suggesting poten-
tial health benefits of the formula supplementation? A
major contribution of Bacteroides (40% of total), staphy-
lococci and E. coli was described in bottle-fed babies
(Harmsen et al., 2000). We observed indeed 10-fold
higher Bacteroidetes titres in infants in control than on test
formula or in breastfed infants. Likewise Ruminococcus
gnavus, a common faecal isolate from humans and rumi-
nants, was increased in control infants. Escherichia coli
was high at enrolment but decreased significantly in abun-
dance in all feeding groups. Similar to the breastfed
group, the test formula compared with the control formula
showed a lower abundance of Peptostreptococcaceae, a
family to which the undesired C. difficile belongs (Yutin
and Galperin, 2013). The test formula induced a signifi-
cant decrease in faecal streptococci, which could be inter-
esting because the specific group of S. lutetiensis
identified in our study was associated in Chinese children
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with diarrhoea for which no known aetiological agent
could be identified (Jin et al., 2013).
Differences were seen in stool properties. Infants in the
test group produced stool with a consistency and stool
colour more comparable with that of the breastfed infants
than to the control group. Although the first property is an
important parameter of gut comfort of the infant, the physi-
ological importance of the second parameter is less clear.
One might suspect an impact of gut microbes on the
catabolism of tetrapyrrolic bile pigments as an end-
product of haem catabolism (stercobilin, biliverdin), but
not much is known about potential health implications of
these changes in stool colour. More interesting is the
difference in stool pH. At 6 weeks of age, infants who
received the test formula had a significantly lower stool pH
than those receiving the control formula. Apparently, the
intestinal microbiota from infants on the test formula pro-
duced – like breastfed infants – more acidic metabolites
than the microbiota of the control groups. Whether this
observation is associated with the higher faecal titre of
bifidobacteria cannot be decided from the available data.
One might suspect that the lower pH is due to the pro-
duction of lactic acid and short chain fatty acids. These
are formed by intestinal bacteria from non-digestible
polysaccharides and oligosaccharides and may have
numerous physiological effects (Brüssow and Parkinson,
2014). Further investigations into the chemical identity of
these compounds conferring a lower faecal pH are clearly
indicated in future studies.
Whatever the health implications of these observations
are, the current study demonstrates that the gut
microbiota can be modulated by a nutritional intervention
in such a way that the diversity and composition of the
microbiota becomes closer to those of breastfed infants.
More intervention studies exploring the diversity of milk
oligosaccharide chemistry (Tannock et al., 2013) will help
transform microbiota research from a descriptive branch
of microbiology into one of applied nutrition to the benefit
of human health.
Material and methods
Trial design and population
This study was registered at ClinicalTrials.gov under the
number NCT01983072 where eligibility criteria and loca-
tions, among other information, are referred. The two
study formulae contained proteins, carbohydrates, fats,
vitamins and minerals in amounts intended for full nutri-
tional support of infants from birth to 4 months of age.
Both were whey-predominant (whey/casein ratio of 70/30)
low-protein (1.8 g/100 kcal) formulas. The study formulas
were manufactured at the Nestlé Product Technology
Center (Konolfingen, Switzerland) and were packaged in
identical cans. Neither parents/caregivers nor investiga-
tors and clinical project managers knew the identity of the
formulas. Infants were exclusively fed their assigned
formula or were fully breastfed ad libitum from enrolment
until 3 months of age.
Faecal DNA extraction
Stool samples were collected for each time point, refrig-
erated at 4°C for a maximum of 10 h after defecation and
kept frozen at −80°C until the microbiota analysis was
carried out. Total DNA was extracted using the QIAamp
DNA Stool Mini Kit (QIAGEN), following the manufactur-
er’s instructions, except for the addition of a series of
mechanical disruption steps (11 × 45 s) using a FastPrep
apparatus and Lysing Matrix B tubes (MP Biochemicals)
(Junick and Blaut, 2012).
Quantitative PCR
Total bacterial cell counts (Nadkarni et al., 2002),
Bifidobacterium (Matsuki et al., 2002), Lactobacillus
(Walter et al., 2001; Heilig et al., 2002) and counts for
individual species of bifidobacteria (Junick and Blaut,
2012) were determined per gram of faeces as previously
described. Bacterial counts were log transformed, and
summary statistics as well as the frequencies of undetec-
table bacterial counts were recorded. Values below the
detection limit were replaced by 5 log g−1 for B. longum
and B. breve, and by 6 log g−1 for the others. The
Wilcoxon rank-sum test was used to compare the groups.
Pyrosequencing and analysis of 16S genes
The 16S variable regions V1–V3 was PCR amplified and
sequenced on Roche 454 GS-FLX-Titanium Sequencer as
previously described (Sanchez et al., 2014). Raw
sequence data were deposited in the GenBank Short Read
Archive (Accession number: SRP064888) and analysed
using MOTHUR V.1.33.0 (Schloss et al., 2009) and QIIME
V.1.8 (Caporaso et al., 2010b) software packages.
Pyrosequencing reads were denoised with the MOTHUR
implementation of PyroNoise (Quince et al., 2009) accord-
ing to the 454 SOP described in Schloss and Westcott
(2011). Chimeras were identified using usearch61 in QIIME
(Edgar et al., 2011). The sequences were then trimmed as
described in the MOTHUR 454 SOP to keep sequences
overlapping the same 16S region. Subsequent analytical
steps were performed in QIIME. Operational taxonomic
units (OTUs) de novo picking at 97% identity was per-
formed using UCLUST (Edgar, 2010). Taxonomy assign-
ment of OTU representative sequences used the RDP
Classifier with confidence threshold of 0.6 (Wang et al.,
2007) on the Greengenes reference database v.13.8
(McDonald et al., 2012). The same sequences were
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aligned using PYNAST (Caporaso et al., 2010a) on the
Greengenes core reference alignment (DeSantis et al.,
2006). The resulting multiple alignments was then filtered
and used to build a phylogenetic tree with FASTTREE (Price
et al., 2010). After quality filtering (Bokulich et al., 2013),
phylogenetic distances between all samples were com-
puted as UniFrac distances (Lozupone and Knight, 2005).
Diversity analyses based on the Unifrac distances were
performed in QIIME, whereas the analyses based on tax-
onomy assignments used the websites Calypso at http://
bioinfo.qimr.edu.au/calypso.
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